

Memo

Reduction of 30-minute observation time for Pfizer COVID-19 vaccine: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendation

Date:	8 March 2021
То:	Jo Gibbs, Director of National Operations, COVID Vaccine Immunisation Programme
Cc:	Juliet Rumball-Smith, Chief Clinical Advisor, COVID-19 Immunisation, Testing and Supply
From:	Dr Ian Town, Chief Science Advisor Dr Caroline McElnay, Director of Public Health
For your:	Information

Purpose of report

1. To outline the COVID-19 Vaccine Technical Advisory Group's recommendation following a request to reconsider the current requirement for individuals to be observed for 30 minutes after receiving the Pfizer COVID-19 vaccine.

Context

- 2. At the CV TAG meeting held on Thursday 4 February 2021, CV TAG decided that individuals must wait for 30 minutes after receiving the Pfizer COVID-19 vaccination. The rates of severe allergic reaction or anaphylaxis after administration of the Pfizer vaccine informed CV TAG's decision to implement a 30-minute observation period.
- 3. This decision was taken as a precautionary measure with an intention to review the requirement following initial experience.
- 4. Data published in the Journal of the American Medical Association (JAMA) since CV TAG last met identifies a reporting rate of anaphylaxis of 4.7 cases/million doses administered with a median time of 10 minutes for symptoms/signs of anaphylaxis to manifest.
- 5. Based on this data, the COVID Vaccine Immunisation programme (CVIP) asked CV TAG to review the 30-minute observation period requirement to align with standard post-vaccination observation periods, which will enable greater on-site efficiencies, remove a barrier to vaccination uptake, and better align with international practices.

Recommendations

- 6. CV TAG members considered the request from the CVIP to review the 30-minute observation period requirement post vaccination. Discussion at the meeting held on Tuesday 2 March 2021 identified three options for consideration:
 - a) Continue to require a 30-minute observation period OR



- b) Reduce the observation period to 20 minutes for people with no history of immediate allergic reaction or anaphylaxis, and utilise a 30 minute observation period for those at higher risk of this event (i.e. who have a history of hypersensitivity to vaccines or any injectable therapy, or of anaphylaxis due to any cause, including those who have a prescribed adrenalin autoinjector);* OR
- c) Reduce the observation period to 20 minutes as a standard practice, with vaccinators encouraged to be flexible around the need for a longer period in some circumstances (e.g. if the person lives in a rural/remote area). *
- 7. The CV TAG recommended that option (c) should be implemented.

la 6 rows

Dr Ian Town

Chief Science Advisor and

Chair of the COVID-19 Vaccine Technical Advisory Group

*This advice would not apply to those who experienced anaphylaxis following the first dose of the Pfizer vaccine - who should not be given a second dose - and those with known hypersensitivity to any of the vaccine excipients for whom the vaccine is contraindicated.